[{"id":"01bffa3c-9006-4894-8107-d61b57731dac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02717962","created_at":"2021-07-05T16:52:37.869Z","updated_at":"2024-07-02T16:35:28.400Z","phase":"Phase 2","brief_title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","source_id_and_acronym":"NCT02717962","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • dianhydrogalactitol (VAL-083)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 03/30/2024","study_completion_date":" 03/30/2024","last_update_posted":"2023-11-22"},{"id":"db290688-b9fc-48ab-8e7b-dd66203a479d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03050736","created_at":"2021-01-18T15:01:27.039Z","updated_at":"2024-07-02T16:35:28.518Z","phase":"Phase 2","brief_title":"Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression","source_id_and_acronym":"NCT03050736","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dianhydrogalactitol (VAL-083)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/17/2017","start_date":" 12/17/2017","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-11-21"},{"id":"e2d15399-6c48-4d6d-b73e-419170efa3e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01478178","created_at":"2021-01-18T06:10:05.513Z","updated_at":"2024-07-02T16:37:26.384Z","phase":"Phase 1/2","brief_title":"Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma","source_id_and_acronym":"NCT01478178","lead_sponsor":"DelMar Pharmaceuticals, Inc.","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dianhydrogalactitol (VAL-083)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-01-20"}]